Medtronic PLC (NYSE:MDT) Given Average Rating of “Moderate Buy” by Brokerages

Medtronic PLC (NYSE:MDT) has been assigned a consensus rating of “Moderate Buy” from the twenty-two research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $100.9375.

Several analysts have recently weighed in on MDT shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Medtronic in a report on Thursday, August 14th. Daiwa Capital Markets raised their price objective on shares of Medtronic from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a report on Friday. UBS Group raised their price objective on shares of Medtronic from $94.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday, August 20th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Medtronic in a report on Friday, July 11th.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president directly owned 35,615 shares in the company, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William R. Jellison acquired 2,500 shares of the firm’s stock in a transaction on Monday, August 25th. The stock was purchased at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the transaction, the director directly owned 5,000 shares in the company, valued at approximately $461,850. The trade was a 100.00% increase in their position. The disclosure for this purchase can be found here. 0.26% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MDT. Cardinal Capital Management Inc. increased its holdings in Medtronic by 2.2% in the third quarter. Cardinal Capital Management Inc. now owns 289,535 shares of the medical technology company’s stock valued at $27,575,000 after purchasing an additional 6,325 shares during the last quarter. Iowa State Bank grew its position in shares of Medtronic by 1.4% during the 3rd quarter. Iowa State Bank now owns 18,435 shares of the medical technology company’s stock worth $1,756,000 after buying an additional 253 shares during the period. Aaron Wealth Advisors LLC increased its stake in shares of Medtronic by 209.1% in the 3rd quarter. Aaron Wealth Advisors LLC now owns 24,871 shares of the medical technology company’s stock valued at $2,369,000 after acquiring an additional 16,826 shares during the last quarter. Shorepoint Capital Partners LLC bought a new stake in shares of Medtronic in the 3rd quarter valued at about $3,401,000. Finally, GAMMA Investing LLC boosted its stake in Medtronic by 18.5% during the 3rd quarter. GAMMA Investing LLC now owns 21,502 shares of the medical technology company’s stock worth $2,048,000 after acquiring an additional 3,351 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors.

Medtronic Stock Performance

NYSE:MDT opened at $97.63 on Tuesday. Medtronic has a 12-month low of $79.29 and a 12-month high of $97.94. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $125.23 billion, a PE ratio of 26.90, a price-to-earnings-growth ratio of 2.57 and a beta of 0.78. The firm has a 50-day moving average price of $92.94 and a 200 day moving average price of $88.48.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm had revenue of $8.58 billion during the quarter, compared to analyst estimates of $8.37 billion. During the same quarter in the prior year, the business posted $1.23 earnings per share. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Research analysts anticipate that Medtronic will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 17th. Shareholders of record on Friday, September 26th will be given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, September 26th. Medtronic’s dividend payout ratio (DPR) is presently 78.24%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.